InMed Stock: New Alzheimer's Treatment Could Transform Neuroinflammation Market

Rhea-AI Filing Summary

InMed Pharmaceuticals has announced promising new preclinical data for their drug candidate INM-901 on June 24, 2025. The research demonstrates significant reduction in inflammation in ex vivo models of neuroinflammation, strengthening the compound's potential as a therapeutic treatment for Alzheimer's disease.

Key points from the 8-K filing:

• The announcement falls under Regulation FD Disclosure (Item 7.01)
• The company is classified as an emerging growth company
• Common shares trade on Nasdaq under symbol INM
• The disclosure is being furnished rather than "filed" under SEC regulations

This development represents a significant milestone in InMed's neurodegenerative disease pipeline, though specific efficacy data and trial details were not disclosed in the filing. The news was signed off by President & CEO Eric A Adams.

Positive

• New preclinical data shows INM-901 significantly reduces inflammation in ex vivo neuroinflammation models, advancing potential Alzheimer's disease treatment development

Negative

• None.

Insights

Pharmaceutical R&D Expert

InMed's INM-901 shows promising anti-inflammatory effects in preclinical neuroinflammation models, marking early progress in Alzheimer's research.

InMed Pharmaceuticals has reported new preclinical data demonstrating that their investigational compound INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. This finding provides early supportive evidence for its potential application in Alzheimer's disease, where neuroinflammation is increasingly recognized as a key pathological component.

In drug development, ex vivo models (using tissues outside living organisms) represent an important early research tool that helps establish biological activity before advancing to more complex studies. While these models provide valuable initial insights, they constitute just one of many steps in the lengthy pharmaceutical development process.

The significance of these results lies in establishing proof-of-concept for INM-901's anti-inflammatory properties specifically in neurological tissues. Neuroinflammation has emerged as a compelling therapeutic target in Alzheimer's research, as chronic inflammation contributes to neuronal damage and disease progression.

For smaller biopharmaceutical companies like InMed, demonstrating biological activity in disease-relevant models represents an important research milestone that helps validate their development programs. These preclinical findings indicate that INM-901 merits continued investigation within their neuroscience pipeline, though substantial additional research would be required to determine whether these early results might translate to clinical benefits.

false 0001728328 A1 0001728328 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 7.01 Regulation FD Disclosure.

On June 24, 2025, the Company announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer’s disease.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		News release, dated June 24, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.
Date: June 24, 2025	By:	/s/ Eric A Adams
		Eric A Adams President & CEO

2

FAQ

What was INM's major announcement in their June 24, 2025 8-K filing?

InMed Pharmaceuticals (INM) announced new preclinical data showing that their drug candidate INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, supporting its potential as a therapeutic candidate for Alzheimer's disease.

What is INM-901's potential therapeutic application according to the June 2025 8-K?

According to the 8-K filing, INM-901 is being developed as a potential therapeutic candidate for Alzheimer's disease, with new preclinical data showing promising results in reducing neuroinflammation.

Who signed InMed Pharmaceuticals' June 2025 8-K filing?

The 8-K filing was signed by Eric A Adams, who serves as President & CEO of InMed Pharmaceuticals Inc.

Is InMed Pharmaceuticals (INM) considered an emerging growth company?

Yes, according to the 8-K filing, InMed Pharmaceuticals is designated as an emerging growth company as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934.

Where are InMed Pharmaceuticals' (INM) shares traded?

InMed Pharmaceuticals' common shares, with no par value, are traded on The Nasdaq Stock Market LLC under the symbol INM.